NCT07463846RecruitingPhase 1/2
A Study to Evaluate ALN-2232 in Participants With Obesity
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 2 Mar 2026
- Primary completion date
- 28 Apr 2027
- Lead sponsor
- Alnylam Pharmaceuticals
- Diseases
- Obesity
- NCT number
- NCT07463846
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 156
- From 2 Mar 2026 to the primary completion date, 28 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving therapies for chronic weight management or antidiabetic medications
- Note: other protocol defined inclusion/exclusion criteria apply
Lab values
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
Other
- All Parts:
Who the study is looking for
- All Parts:
- Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2
- Has a hemoglobin A1c (HbA1c) \<6.5%
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Mount Royal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.